Agrylin en es it fr

Agrylin Brand names, Agrylin Analogs

Agrylin Brand Names Mixture

  • No information avaliable

Agrylin Chemical_Formula


Agrylin RX_link

Agrylin fda sheet

Agrylin FDA

Agrylin msds (material safety sheet)

Agrylin MSDS

Agrylin Synthesis Reference

No information avaliable

Agrylin Molecular Weight

256.088 g/mol

Agrylin Melting Point

280 oC

Agrylin H2O Solubility

Very slightly soluble

Agrylin State


Agrylin LogP


Agrylin Dosage Forms

Capsules (0.5 mg or 1 mg)

Agrylin Indication

For the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.

Agrylin Pharmacology

Anagrelide is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia). It works by inhibiting the maturation of megakaryocytes into platelets. The exact mechanism of action is unclear, although it is known to be a potent (IC50 = 36nM) inhibitor of phosphodiesterase-III.

Agrylin Absorption

No information avaliable

Agrylin side effects and Toxicity

There are no reports of overdosage with anagrelide, however thrombocytopenia, which can potentially cause bleeding, is expected from overdosage. Single oral doses of anagrelide at 2,500, 1,500 and 200 mg/kg in mice, rats and monkeys, respectively, were not lethal. Symptoms of acute toxicity were: decreased motor activity in mice and rats and softened stools and decreased appetite in monkeys.

Agrylin Patient Information

Agrylin Organisms Affected

Humans and other mammals